A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
ApexOnco Front Page
Recent articles
Talapro-3 could help move Talzenna into earlier prostate cancer.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
The company is set to start a phase 2/3 trial this month.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The group will start a pivotal trial of samuraciclib following promising second-line results.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
